Skin Analytics Case Study

Leicester, Leicestershire and Rutland ICB





Background

Skin Analytics partnered with Leicester, Leicestershire and Rutland ICB, University Hospitals Leicester, Leicester City CCG and Primary care to deliver a new skin cancer pathway for their patient population. There was a need for change in the area with skin cancer pathways becoming overwhelmed despite local initiatives. Collaborating to deploy a system wide solution, this new pathway will see thousands of patients, discharging benign lesions earlier in the pathway and reserving specialist capacity for those most at need of urgent care.

Challenge

Community led GPwSI dermatology service already running, but still not enough.

- Increased referrals (+30% above pre-pandemic levels).
- Increased conversion factor to cancer: from 5-7% to 12-15%.
- 7 out of the 15 recommended Whole Time Equivalents (WTE)
- Capacity for non cancer outpatient appointments reduced due to backlog of 2WW patients
- Dermatology department overloaded (4th busiest dermatology department in UK)
- Inequalities around the city due to pockets of deprivation and only one main city centre site for patients


Goals

Working in collaboration across the system, the team wanted to improve their skin cancer pathways utilising a wider workforce to address the backlog and to reduce delays in skin cancer detection and treatment.

- Operational efficiencies: reduce outpatient appointments to recover from the growing patient backlog.
- Perform against national targets: 14-day & 28 day target.
- **Better patient experience: r**educe delays for diagnosis and treatment of skin cancer and offer earlier reassurance for the majority of referrals.



Pathway



Impact

	REF Volume		2WW (%)		RTT (%)	
	2021	2022	2021	2022	2021	2022
Apr	668	753	95.1	90.3	64.3	43.8
May	512	890	77.9	92.3	64.8	65.2
Jun	787	744	18.2	90.6	68.5	80.4
Jul	994	850	23.8	90.9	-	85.7
Aug	1037	1097	57.9	90.0	64	90.6
Sep	799	1100	90.4	91.3	58.8	87.2
Avg.	799.5	905.7	60.6	90.9	64.1	75.5

3,094

Patients seen through pathway

59%

Patients avoided a F2F dermatology appointment

~33%

Trust discharges (Al supported 18%)